Langenberg & Co. Trims Keryx Biopharmaceuticals (KERX) to Hold
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Langenberg & Company downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) to Hold.
On the session, Keryx is moving lower. Shares are down well over 7 percent in early trading.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
On the session, Keryx is moving lower. Shares are down well over 7 percent in early trading.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
